Neuralstem Reports Year End 2017 Fiscal Results and Business Update – GlobeNewswire (press release)
– Neuralstem Releases Full Data Set for NSI-189 MDD Trial Showing Patient Rated Outcome and Cognitive Benefits – Nature Medicine Paper Demonstrates Benefit of NSI-566 on Paralysis in Non-Human Primates GERMANTOWN, Md., April 02, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural…